ClinicalTrials.gg
RecruitingNCT07658365O-tFUSUpdated Oct 6, 2026

Olfactory Transcranial Focused Ultrasound

An interventional study of transcranial focused ultrasound (tFUS) in Healthy and Olfaction, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 6, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Anosmia with a site in United States — 17 open to participants now, 20 under way, 1 of them phase 3. Anosmia · United States.

Planned enrollment
34th of 43
28 · median 51
Started
2026
with 5 others
No phase
19 of 59
7 open now
Primary completion
2028-04
later than 11 of 19 live
Registered
56th of 59
by date
Lead sponsor
3 of 59
Medical University of South Carolina

Among the 59 studies in Anosmia with a site in United States, this one is the 34th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2026, is one of 19 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 56th registered.

Anosmia

180 studies on the registry are indexed under Anosmia; 45 are open to participants now.

Browse Anosmia studies →

Open to participants now

17 of the 59 studies in Anosmia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Anosmia studies recruiting now, 14 (45%) set no upper age limit and 9 (29%) stop at 75 or younger; 3 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Anosmia with a site in United States, or all of them as a file.
02

Study summary

This study investigates the causal effects of low-intensity transcranial focused ultrasound (tFUS) on odor valence perception and odor-elicited avoidance behaviors in healthy adults. Participants undergo sham and active tFUS targeting the amygdala (AMYG) and ventral striatal olfactory tubercle (VSOT) in a within-subject, randomized, sham-controlled crossover design. Outcomes include subjective odor ratings and objective neurophysiological and behavioral indices of odor valence processing. This research is exploratory and mechanistic in nature and is not intended to evaluate clinical safety or therapeutic efficacy.

03

Conditions studied

  • Healthy
  • Olfaction

Browse trials for

Keywords

  • healthy volunteer
  • electroencephalography (EEG)
  • magnetic resonance imaging (MRI)
  • odors
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • Healthy adult volunteers
  • Normal olfactory function (Sniffin' Sticks total TDI ≥ 30.75)
  • Ability to provide
  • English fluency sufficient for task completion

Exclusion criteria

Exclusion Criteria:

  • MRI or tFUS (e.g., metal implants, claustrophobia, pregnancy)
  • Sinonasal conditions affecting airflow or smell
  • Current use of medications that alter olfaction
  • Positive urine drug screen
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Active tFUS targeting the Amygdala (AMYG)

    Active tFUS of the bilateral Amygdala randomized at one of the three stimulation visits

    Device: transcranial focused ultrasound (tFUS)

  • Experimental
    Active tFUS targeting the Ventral Striatal Olfactory Tubercle (VSOT)

    Active tFUS of the bilateral VSOT randomized at one of the three stimulation visits

    Device: transcranial focused ultrasound (tFUS)

  • Sham comparator
    Sham tFUS

    Sham tFUS randomized at one of three stimulation visits

    Device: transcranial focused ultrasound (tFUS)

Interventions

  • Devicetranscranial focused ultrasound (tFUS)

    non-invasive brain stimulation using tFUS

06

What researchers measure

Primary outcomes

  1. Odor Valence Rating

    Participant rating of odor pleasantness on a 0-100 mm visual analog scale (e.g., unpleasant → pleasant)

    Time frame: from the baseline visit until the third follow-up visit (about 1 month)

  2. Late Positive Potential

    Mean EEG amplitude (400-800 ms) at centro-parietal sites to olfactory-visual stimuli

    Time frame: from the baseline visit until the third follow-up visit (about 1 month)

  3. Sniff Volume

    Total nasal airflow (in mL) per odor trial, measured via nasal cannula or spirometer

    Time frame: from the baseline visit until the third follow-up visit (about 1 month)

  4. Corrugator Supercilii EMG Activity

    Mean EMG amplitude from facial muscle sensitive to negative affect and aversion

    Time frame: from the baseline visit until the third follow-up visit (about 1 month)

Secondary outcomes

  1. Odor Intensity Rating

    Participant rating of odor intensity on a 0-100 mm visual analog scale (e.g., not at all → extremely)

    Time frame: from the baseline visit until the third follow-up visit (about 1 month)

  2. Odor Avoidance Rating

    Participant rating of their desire to avoid the odor on a 0-100 mm visual analog scale (e.g., "not at all" → "extreme")

    Time frame: from the baseline visit until the third follow-up visit (about 1 month)

  3. Sniff Rate

    Breaths per min or per trial window in response to odor exposure

    Time frame: from the baseline visit until the third follow-up visit (about 1 month)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Houghton DC, Uhde TW, Borckardt JJ, Cortese BM. Exploratory Investigation of a Brief Cognitive Behavioral Intervention and Transcranial Direct Current Stimulation on Odor Sensitivity. Psychosom Med. 2019 May;81(4):389-395. doi: 10.1097/PSY.0000000000000679. PubMed 30762663 ↗
  • Badran BW, Gruber EM, O'Leary GH, Austelle CW, Huffman SM, Kahn AT, McTeague LM, Uhde TW, Cortese BM. Electrical stimulation of the trigeminal nerve improves olfaction in healthy individuals: A randomized, double-blind, sham-controlled trial. Brain Stimul. 2022 May-Jun;15(3):761-768. doi: 10.1016/j.brs.2022.05.005. Epub 2022 May 11. PubMed 35561963 ↗

Individual participant data

Plan to share: Yes — Results (raw data and summarized) will be shared. A final de-identified data set will be made available for retrieval and analysis through OpenNeuro.org. All study protocols, including detailed descriptions of the study structure, data formats, and analytical methods, will be made available to ensure transparency and reproducibility. Associated documentation, including data dictionaries, codebooks, and analysis scripts, will be provided to enable others to replicate our methodology and build upon our findings. Data will be made available after publication of the findings.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be made available after publication of the findings. Data will be retained long enough to support the reproducibility of our published findings, the re-use by others, and as long as it is of value to the research community and/or public.

Access criteria: Data will be identifiable through a search engine for the title and other key words including the Modality: EEG, Task: odor-enhanced visual processing, Diagnosis: healthy controls, and Study Type: crossover. Additionally, we will provide the Openneuro Accession Number in any study communication.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2028, 18 months after the start.

Of 50 non-industry interventional studies with no phase under Anosmia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 18 months is below that.

Counting every sponsor, half of 50 studies reached it within 28 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 22, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
1 site added — first site in United States
Show site
  • Medical University of South Carolina · Charleston, United States
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Medical University of South Carolina · Charleston, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07658365
Responsible party
Bernadette Cortese (Associate Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Jun 22, 2026
Start date
Oct 1, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Nicole Cash, Study Coordinator
Contact
cashni@musc.edu
843-790-3449

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion